Investor Relations Contact:
Anacor is a biopharmaceutical company focused on discovering, developing and commercializing novel small molecule therapeutics derived from its novel boron chemistry platform. We currently have five product candidates in clinical development. Our three lead product candidates include two topically administered dermatologic compounds— tavaborole (formerly AN2690) , an antifungal for the treatment of onychomycosis, and AN2728, an anti-inflammatory for the treatment of psoriasis, as well as a systemic antibiotic for the treatment of infections caused by Gram-negative bacteria—GSK2251052, or GSK '052 (formerly referred to as AN3365). In addition, we are developing AN2718 as a topical antifungal product candidate for the treatment of onychomycosis and skin fungal infections, and AN2898 as a topical anti-inflammatory product candidate for the treatment of psoriasis and atopic dermatitis. We have entered into and are seeking partnerships to expand the therapeutic application and commercial value of our boron chemistry platform.
Mar 6, 2014
Anacor Pharmaceuticals Announces 2013 Fourth Quarter and Year End Financial Results Conference Call and Webcast
Feb 27, 2014
Anacor Pharmaceuticals Announces Successful Completion of End-of-Phase 2 Meeting With FDA for the Treatment of Mild-to-Moderate Atopic Dermatitis With AN2728
View all »Events & Presentations
Mar 13, 2014 at 2:00 PM PT
Anacor Fourth Quarter 2013 Financial Results Conference Call
Mar 3, 2014 at 3:30 PM ET
Cowen & Company 34th Annual Health Care Conference
Dec 4, 2013 at 12:00 PM ET
25th Annual Piper Jaffray Healthcare Conference
Receive Email Alerts
Sign up to receive e-mail alerts
whenever Anacor posts new information to the site.